2-(4-(2-氨基乙基)苯氧基)-2-甲基丙酸甲酯 | 190182-03-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 2-(4-(2-氨基乙基)苯氧基)-2-甲基丙酸甲酯
• 英文名称: methyl 2-[4-(2-aminoethyl)phenoxy]-2-methylpropanoate
• 英文别名: methyl 2-[4-(2-aminoethyl)-phenoxy]-2-methylpropionate
• CAS: 190182-03-7
• 化学式: C₁₃H₁₉NO₃
• 分子量: 237.299
• InChiKey: ZHPJLBQLCHSICY-UHFFFAOYSA-N

物化性质

• 沸点：
  338.9±22.0 °C(Predicted)
• 密度：
  1.081±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  17
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.46
• 拓扑面积：
  61.6
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  2-(4-(2-氨基乙基)苯氧基)-2-甲基丙酸甲酯 在 硼烷四氢呋喃络合物 、 1-羟基苯并三唑 、 N,N'-二异丙基碳二亚胺 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 反应 15.5h， 生成 methyl 2-[4-(2-heptylaminoethyl)phenoxy]-2-methylpropanoate
  参考文献：
  名称：

  Synthesis, Characterization and Biological Evaluation of Ureidofibrate-Like Derivatives Endowed with Peroxisome Proliferator-Activated Receptor Activity

  摘要：

  A series of ureidofibrate-like derivatives was prepared and assayed for their PPAR functional activity. A calorimetric approach was used to characterize PPAR gamma-ligand interactions, and docking experiments and X-ray studies were performed to explain the observed potency and efficacy. R-1 and S-1 were selected to evaluate several aspects of their biological activity. In an adipogenic assay, both enantiomers increased the expression of PPAR gamma target genes and promoted the differentiation of 3T3-L1 fibroblasts to adipocytes. In vivo administration of these compounds to insulin resistant C57Bl/6J mice fed a high fat diet reduced visceral fat content and body weight. Examination of different metabolic parameters showed that R-1 and S-1 are insulin sensitizers. Notably, they also enhanced the expression of hepatic PPAR alpha target genes indicating that their in vivo effects stemmed from an activation of both PPAR alpha and gamma. Finally, the capability of R-1 and S-1 to inhibit cellular proliferation in colon cancer cell lines was also evaluated.

  DOI：

  10.1021/jm201306q
• 作为产物：
  描述：

  2-(4-溴苯氧基)-2-甲基丙酸 在 Wilkinson's catalyst 、 hydrazine hydrate 、 硫酸 、 氢气 、 palladium diacetate 、 N,N-二异丙基乙胺 、 三(邻甲基苯基)磷 作用下， 以 四氢呋喃 、 乙醇 、 乙腈 为溶剂， 20.0 ℃ 、405.33 kPa 条件下， 反应 32.0h， 生成 2-(4-(2-氨基乙基)苯氧基)-2-甲基丙酸甲酯
  参考文献：
  名称：

  Synthesis, Characterization and Biological Evaluation of Ureidofibrate-Like Derivatives Endowed with Peroxisome Proliferator-Activated Receptor Activity

  摘要：

  A series of ureidofibrate-like derivatives was prepared and assayed for their PPAR functional activity. A calorimetric approach was used to characterize PPAR gamma-ligand interactions, and docking experiments and X-ray studies were performed to explain the observed potency and efficacy. R-1 and S-1 were selected to evaluate several aspects of their biological activity. In an adipogenic assay, both enantiomers increased the expression of PPAR gamma target genes and promoted the differentiation of 3T3-L1 fibroblasts to adipocytes. In vivo administration of these compounds to insulin resistant C57Bl/6J mice fed a high fat diet reduced visceral fat content and body weight. Examination of different metabolic parameters showed that R-1 and S-1 are insulin sensitizers. Notably, they also enhanced the expression of hepatic PPAR alpha target genes indicating that their in vivo effects stemmed from an activation of both PPAR alpha and gamma. Finally, the capability of R-1 and S-1 to inhibit cellular proliferation in colon cancer cell lines was also evaluated.

  DOI：

  10.1021/jm201306q

文献信息

• Synthesis of Benzoisoselenazolones via Rh(III)‐Catalyzed Direct Annulative Selenation by Using Elemental Selenium
  作者：Qing‐Feng Xu‐Xu、Yuji Nishii、Yuta Uetake、Hidehiro Sakurai、Masahiro Miura

  DOI：10.1002/chem.202103485

  日期：2021.12.20

  A Rh(III)-catalyzed direct selenium annulation by using stable and tractable elemental selenium is developed. A series of benzamides as well as acrylamides were successfully coupled with selenium under mild reaction conditions to give isoselenazolone derivatives. An unprecedented selenation mechanism involving an electrophilic Se(IV) species as the reactive selenium donor is proposed based on the designed

  使用稳定且易处理的元素硒开发了Rh(III) 催化的直接硒环化。在温和的反应条件下，一系列苯甲酰胺和丙烯酰胺与硒成功偶联，得到异硒唑酮衍生物。基于设计的控制实验、X 射线吸收光谱和计算研究，提出了一种前所未有的硒化机制，涉及亲电子 Se(IV) 物种作为反应性硒供体。
• [EN] HPPARS ACTIVATORS<br/>[FR] ACTIVATEURS DE HPPARS
  申请人：SMITHKLINE BEECHAM CORP

  公开号：WO2003074495A1

  公开（公告）日：2003-09-12

  Compounds of formula (1) or a pharmaceutically acceptable salt, solvate, acid isostere, or hydrolyzable ester thereof, are disclosed. Methods of making and using the compounds are also disclosed. In particular methods for treating diseases or conditions associated with one or more of human PPAR alpha, gamma, or delta ('hPPARs') comprising administration of a therapeutically effective amount of a compound of formula (1), are disclosed.

  公式（1）的化合物或其药学上可接受的盐、溶剂合物、酸异构体或可水解酯已被披露。还披露了制备和使用这些化合物的方法。具体披露了用于治疗与人类PPARα、γ或δ（'hPPARs'）中的一个或多个相关疾病或症状的方法，包括给予公式（1）的化合物的治疗有效量。
• Hppars activators
  申请人：Cadilla Rodolfo

  公开号：US20050137212A1

  公开（公告）日：2005-06-23

  Compounds of formula (1) or a pharmaceutically acceptable salt, solvate, acid isostere, or hydrolyzable ester thereof, are disclosed. Methods of making and using the compounds are also disclosed. In particular methods for treating diseases or conditions associated with one or more of human PPAR alpha, gamma, or delta (“hPPARs”) comprising administration of a therapeutically effective amount of a compound of formula (1), are disclosed.

  本发明揭示了化学式（1）或其药学上可接受的盐、溶剂化物、酸同位素或可水解酯的化合物。本发明还揭示了制备和使用这些化合物的方法。特别是揭示了治疗与人类PPAR alpha、gamma或delta（“hPPARs”）中的一个或多个相关的疾病或病状的方法，包括给予化学式（1）的化合物的治疗有效量。
• hPPARs activators
  申请人：SmithKline Beecham Corporation

  公开号：US07319104B2

  公开（公告）日：2008-01-15

  Compounds of formula (1) or a pharmaceutically acceptable salt, solvate, acid isostere, or hydrolyzable ester thereof, are disclosed. Methods of making and using the compounds are also disclosed. In particular methods for treating diseases or conditions associated with one or more of human PPAR alpha, gamma, or delta (“hPPARs”) comprising administration of a therapeutically effective amount of a compound of formula (1), are disclosed

  公开了化学式（1）或其药学上可接受的盐、溶剂化物、酸同位素或可水解酯的化合物。还公开了制备和使用这些化合物的方法。特别是公开了治疗与人类PPARα、γ或δ（“hPPARs”）中的一个或多个相关的疾病或病状的方法，包括给予化合物（1）的治疗有效量的行政部门。
• HPPARS ACTIVATORS
  申请人：SMITHKLINE BEECHAM CORPORATION

  公开号：EP1480957A1

  公开（公告）日：2004-12-01